FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071180011> ?p ?o ?g. }

• W2071180011 endingPage "501" @default.
• W2071180011 startingPage "492" @default.
• W2071180011 abstract "We conducted a multicenter randomized clinical trial to determine the optimal treatment strategy against chronic hepatitis C virus (HCV) with genotype 1b and a high viral load (G1b/high). The study subjects included 153 patients with G1b/high. Patients were initially treated with PEG-IFNα-2a alone and then randomly assigned to receive different treatment regimens. Ribavirin (RBV) was administered to all patients with HCV RNA at week 4. Patients negative for HCV RNA at week 4 were randomly assigned to receive PEG-IFNα-2a (group A) or PEG-IFNα-2a/RBV (group B). Patients who showed HCV RNA at week 4 but were negative at week 12 were randomly assigned to receive weekly PEG-IFNα-2a (group C) or biweekly therapy (group D). Patients who showed HCV RNA at week 12 but were negative at week 24 were randomly assigned to receive PEG-IFNα-2a/RBV (group E) or PEG-IFNα-2a/RBV/fluvastatin (group F). Overall, the rate of sustained virological response (SVR) was 46 % (70/153). The total SVR rate in the group (A, D, and F) of response-guided therapy was significantly higher than that in the group (B, C, and E) of conventional therapy [70 % (38/54) versus 52 % (32/61), p = 0.049]. Although IL28-B polymorphism and Core 70 mutation were significantly associated with efficacy, patients with rapid virological response (RVR) and complete early virological response (cEVR) achieved high SVR rates regardless of their status of IL-28B polymorphism and Core 70 mutation. In addition to knowing the IL-28B polymorphism and Core 70 mutation status, understanding the likelihood of virological response during treatment is critical in determining the appropriate treatment strategy." @default.
• W2071180011 created "2016-06-24" @default.
• W2071180011 creator A5010907477 @default.
• W2071180011 creator A5015485871 @default.
• W2071180011 creator A5016903737 @default.
• W2071180011 creator A5027049654 @default.
• W2071180011 creator A5031516587 @default.
• W2071180011 creator A5032900701 @default.
• W2071180011 creator A5041576626 @default.
• W2071180011 creator A5052342396 @default.
• W2071180011 creator A5061904257 @default.
• W2071180011 creator A5063339600 @default.
• W2071180011 creator A5065142000 @default.
• W2071180011 creator A5067005093 @default.
• W2071180011 creator A5085548325 @default.
• W2071180011 creator A5091812145 @default.
• W2071180011 date "2013-03-30" @default.
• W2071180011 modified "2023-10-01" @default.
• W2071180011 title "Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study" @default.
• W2071180011 cites W1500202556 @default.
• W2071180011 cites W1517300131 @default.
• W2071180011 cites W1887558851 @default.
• W2071180011 cites W1898531773 @default.
• W2071180011 cites W1975507313 @default.
• W2071180011 cites W1977252373 @default.
• W2071180011 cites W1978892007 @default.
• W2071180011 cites W1987002413 @default.
• W2071180011 cites W1987749699 @default.
• W2071180011 cites W1988547147 @default.
• W2071180011 cites W1991536866 @default.
• W2071180011 cites W1992293619 @default.
• W2071180011 cites W1993938603 @default.
• W2071180011 cites W1998859748 @default.
• W2071180011 cites W2007243306 @default.
• W2071180011 cites W2016205218 @default.
• W2071180011 cites W2024049300 @default.
• W2071180011 cites W2026614040 @default.
• W2071180011 cites W2026847690 @default.
• W2071180011 cites W2027252289 @default.
• W2071180011 cites W2027545702 @default.
• W2071180011 cites W2030736973 @default.
• W2071180011 cites W2039563022 @default.
• W2071180011 cites W2044695125 @default.
• W2071180011 cites W2048266689 @default.
• W2071180011 cites W2048428237 @default.
• W2071180011 cites W2056418842 @default.
• W2071180011 cites W2057967679 @default.
• W2071180011 cites W2061431912 @default.
• W2071180011 cites W2063285149 @default.
• W2071180011 cites W2068111057 @default.
• W2071180011 cites W2071124826 @default.
• W2071180011 cites W2071586067 @default.
• W2071180011 cites W2075660007 @default.
• W2071180011 cites W2083563449 @default.
• W2071180011 cites W2086414517 @default.
• W2071180011 cites W2118871178 @default.
• W2071180011 cites W2127685726 @default.
• W2071180011 cites W2142337801 @default.
• W2071180011 cites W2143412399 @default.
• W2071180011 cites W2144792064 @default.
• W2071180011 cites W2155820299 @default.
• W2071180011 cites W2165880492 @default.
• W2071180011 cites W2168229737 @default.
• W2071180011 cites W2335845212 @default.
• W2071180011 cites W2508099985 @default.
• W2071180011 doi "https://doi.org/10.1007/s00535-013-0785-2" @default.
• W2071180011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3953545" @default.
• W2071180011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23543311" @default.
• W2071180011 hasPublicationYear "2013" @default.
• W2071180011 type Work @default.
• W2071180011 sameAs 2071180011 @default.
• W2071180011 citedByCount "4" @default.
• W2071180011 countsByYear W20711800112014 @default.
• W2071180011 countsByYear W20711800112016 @default.
• W2071180011 crossrefType "journal-article" @default.
• W2071180011 hasAuthorship W2071180011A5010907477 @default.
• W2071180011 hasAuthorship W2071180011A5015485871 @default.
• W2071180011 hasAuthorship W2071180011A5016903737 @default.
• W2071180011 hasAuthorship W2071180011A5027049654 @default.
• W2071180011 hasAuthorship W2071180011A5031516587 @default.
• W2071180011 hasAuthorship W2071180011A5032900701 @default.
• W2071180011 hasAuthorship W2071180011A5041576626 @default.
• W2071180011 hasAuthorship W2071180011A5052342396 @default.
• W2071180011 hasAuthorship W2071180011A5061904257 @default.
• W2071180011 hasAuthorship W2071180011A5063339600 @default.
• W2071180011 hasAuthorship W2071180011A5065142000 @default.
• W2071180011 hasAuthorship W2071180011A5067005093 @default.
• W2071180011 hasAuthorship W2071180011A5085548325 @default.
• W2071180011 hasAuthorship W2071180011A5091812145 @default.
• W2071180011 hasBestOaLocation W20711800111 @default.
• W2071180011 hasConcept C104317684 @default.
• W2071180011 hasConcept C126322002 @default.
• W2071180011 hasConcept C135763542 @default.
• W2071180011 hasConcept C168563851 @default.
• W2071180011 hasConcept C203014093 @default.
• W2071180011 hasConcept C2522874641 @default.
• W2071180011 hasConcept C2776178377 @default.
• W2071180011 hasConcept C2776235749 @default.

• next